Evidence map›Paper›PMID 39293807›Full record

ArticleBriefings in bioinformatics2024

ACP-CapsPred: an explainable computational framework for identification and functional prediction of anticancer peptides based on capsule network.

Lantian Yao, Peilin Xie, Jiahui Guan, Chia-Ru Chung, Wenyang Zhang, Junyang Deng, Yixian Huang, Ying-Chih Chiang, Tzong-Yi Lee

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lantian YaoKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Peilin XieKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Jiahui GuanKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Chia-Ru ChungDepartment of Computer Science and Information Engineering, National Central University, 300 Zhongda Road, Taoyuan 320317, Taiwan.
Wenyang ZhangSchool of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Junyang DengSchool of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Yixian HuangSchool of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Ying-Chih ChiangKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, Shenzhen 518172, China.
Tzong-Yi LeeInstitute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, 1001 Daxue Road, Hsinchu 300093, Taiwan.

Funding

Center for Intelligent Drug Systems and Smart Bio-devicesFeatured Areas Research Center ProgramGuangdong Province Basic and Applied Basic Research Fund 2021A1515012447Higher Education Sprout Project and Yushan Young Fellow Program 112C1N084CKobilka Institute of Innovative Drug DiscoveryMinistry of EducationNational Natural Science Foundation of China 32070659National Science and Technology Council NSTC 112-2321-B-A49-016Shenzhen Science and Technology Innovation Commission JCYJ20230807114206014The Chinese University of Hong Kong
6 · The paper itself

Abstract

Cancer is a severe illness that significantly threatens human life and health. Anticancer peptides (ACPs) represent a promising therapeutic strategy for combating cancer. In silico methods enable rapid and accurate identification of ACPs without extensive human and material resources. This study proposes a two-stage computational framework called ACP-CapsPred, which can accurately identify ACPs and characterize their functional activities across different cancer types. ACP-CapsPred integrates a protein language model with evolutionary information and physicochemical properties of peptides, constructing a comprehensive profile of peptides. ACP-CapsPred employs a next-generation neural network, specifically capsule networks, to construct predictive models. Experimental results demonstrate that ACP-CapsPred exhibits satisfactory predictive capabilities in both stages, reaching state-of-the-art performance. In the first stage, ACP-CapsPred achieves accuracies of 80.25% and 95.71%, as well as F1-scores of 79.86% and 95.90%, on benchmark datasets Set 1 and Set 2, respectively. In the second stage, tasked with characterizing the functional activities of ACPs across five selected cancer types, ACP-CapsPred attains an average accuracy of 90.75% and an F1-score of 91.38%. Furthermore, ACP-CapsPred demonstrates excellent interpretability, revealing regions and residues associated with anticancer activity. Consequently, ACP-CapsPred presents a promising solution to expedite the development of ACPs and offers a novel perspective for other biological sequence analyses.

Indexed as

Antineoplastic AgentsComputational BiologyNeural Networks, ComputerPeptidesDatabases, ProteinHumansNeoplasmsAntineoplastic AgentsPeptidesanticancer peptidesbioinformaticscancerscapsule networksdrug discoverysequence analysis

Identifiers

PMID39293807
PMCPMC11410379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.